loading
Gain Therapeutics Inc stock is traded at $1.99, with a volume of 377.40K. It is up +2.05% in the last 24 hours and up +10.56% over the past month. Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
See More
Previous Close:
$1.95
Open:
$1.92
24h Volume:
377.40K
Relative Volume:
1.40
Market Cap:
$56.60M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-1.8091
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
+11.17%
1M Performance:
+10.56%
6M Performance:
+24.37%
1Y Performance:
+56.69%
1-Day Range:
Value
$1.8903
$2.044
1-Week Range:
Value
$1.62
$2.044
52-Week Range:
Value
$0.89
$3.19

Gain Therapeutics Inc Stock (GANX) Company Profile

Name
Name
Gain Therapeutics Inc
Name
Phone
(301) 500-1556
Name
Address
4800 HAMPDEN LANE, BETHESDA
Name
Employee
25
Name
Twitter
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
GANX's Discussions on Twitter

Compare GANX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GANX
Gain Therapeutics Inc
1.99 56.60M 210.70K -21.37M -21.10M -1.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.40 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.25 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
254.49 28.51B 3.81B -644.79M -669.77M -6.24

Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-07-25 Initiated Scotiabank Sector Outperform
Dec-06-24 Initiated ROTH MKM Buy
Aug-14-24 Resumed Oppenheimer Outperform
Apr-12-21 Initiated BTIG Research Buy
Apr-12-21 Initiated Oppenheimer Outperform

Gain Therapeutics Inc Stock (GANX) Latest News

pulisher
Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView

Jun 18, 2025
pulisher
Jun 16, 2025

SpringWorks Therapeutics (SWTX) Continues Strong Yearly Run, Showing Over 29% YTD Gain - Daily Chhattisgarh News

Jun 16, 2025
pulisher
Jun 15, 2025

Stellantis (NYSE:STLA) Receives Consensus Rating of “Hold” from Analysts - Defense World

Jun 15, 2025
pulisher
Jun 15, 2025

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of “Buy” by Analysts - Defense World

Jun 15, 2025
pulisher
Jun 15, 2025

Pharmaceutical Stocks Worth Watching – June 13th - Defense World

Jun 15, 2025
pulisher
Jun 13, 2025

Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - MSN

Jun 13, 2025
pulisher
Jun 11, 2025

CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

Gain Therapeutics to Participate in Upcoming Investor Conferences - Bluefield Daily Telegraph

Jun 10, 2025
pulisher
Jun 10, 2025

Gain Therapeutics Opens Access to Management: CEO Featured at Two Major Biotech Investor Conferences - Stock Titan

Jun 10, 2025
pulisher
Jun 08, 2025

Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share (NASDAQ:AQST) - Seeking Alpha

Jun 08, 2025
pulisher
Jun 04, 2025

Telix Pharmaceuticals (ASX:TLX) Gains Portugal Approval for Illuccix in Prostate Cancer Detection - Yahoo Finance

Jun 04, 2025
pulisher
Jun 03, 2025

Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - sharewise

Jun 03, 2025
pulisher
Jun 03, 2025

Northern Trust Corp Raises Holdings in Banco Bradesco S.A. (NYSE:BBDO) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Northern Trust Corp Invests $208,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Northern Trust Corp Has $226,000 Position in LightPath Technologies, Inc. (NASDAQ:LPTH) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Purchased by Northern Trust Corp - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

i-80 Gold Corp. (NYSE:IAUX) Receives $3.50 Average PT from Brokerages - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Northern Trust Corp Increases Stock Holdings in PetMed Express, Inc. (NASDAQ:PETS) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Northern Trust Corp Purchases 10,466 Shares of United-Guardian, Inc. (NASDAQ:UG) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Northern Trust Corp Grows Stock Holdings in Bridger Aerospace Group Holdings, Inc. (NASDAQ:BAER) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Northern Trust Corp Increases Stock Position in NeueHealth, Inc. (NYSE:NEUE) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews

Jun 02, 2025
pulisher
May 29, 2025

Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting - The Manila Times

May 29, 2025
pulisher
May 29, 2025

Gain Therapeutics, Inc. Announces Oral Presentation at GBA1 Meeting 2025 in Montreal - Nasdaq

May 29, 2025
pulisher
May 29, 2025

Gain Therapeutics' Chief Medical Officer Set to Reveal Latest GBA1 Therapeutic Developments in Montreal - Stock Titan

May 29, 2025
pulisher
May 28, 2025

Gain Therapeutics Files $100 Million Mixed Shelf - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Gain Therapeutics (GANX) Pursues $100 Million Securities Offerin - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Gain Therapeutics (GANX) Pursues $100 Million Securities Offering | GANX Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings - Benzinga

May 28, 2025
pulisher
May 23, 2025

CytomX Therapeutics Inc’s (CTMX) 4.41% Gain Is A Reason To Reconsider. - Stocksregister

May 23, 2025
pulisher
May 22, 2025

HC Wainwright Brokers Increase Earnings Estimates for GANX - Defense World

May 22, 2025
pulisher
May 21, 2025

Gotham Asset Management LLC Sells 176,437 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World

May 21, 2025
pulisher
May 21, 2025

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Buy” by Analysts - Defense World

May 21, 2025
pulisher
May 20, 2025

GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com

May 20, 2025
pulisher
May 20, 2025

Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright - Defense World

May 20, 2025
pulisher
May 19, 2025

Gain Therapeutics (GANX) Maintains 'Buy' Rating with $8 Price Ta - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Roth Capital Predicts Reduced Earnings for Gain Therapeutics - Defense World

May 19, 2025
pulisher
May 15, 2025

Gain Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 15, 2025
pulisher
May 14, 2025

Gain Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

Gain (GANX) Advances Parkinson's Treatment in Phase 1b Trials | - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Gain Therapeutics, Inc. Reports Q1 2025 Financial Results and Corporate Update, Highlights Progress in Parkinson’s Disease Drug Development - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Gain Therapeutics' Parkinson's Drug Shows Promise: Key Biomarker Data Coming Mid-2025 - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Zevra Therapeutics Q1 Net Loss Narrows, Revenue Rises; Shares Gain After Hours - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Crude Oil Gains 3%; US Inflation Eases In April - Benzinga

May 13, 2025
pulisher
May 12, 2025

Gain Therapeutics (GANX) Showcases Promising Parkinson's Treatme - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Gain Therapeutics, Inc. Presents New Evidence for GT-02287 as Potential Disease-Modifying Therapy for Parkinson’s Disease at IAPRD 30th World Congress - Nasdaq

May 12, 2025
pulisher
May 12, 2025

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - The Manila Times

May 12, 2025
pulisher
May 12, 2025

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders - TradingView

May 12, 2025
pulisher
May 11, 2025

Gain Therapeutics (GANX) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025

Gain Therapeutics Inc Stock (GANX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Gain Therapeutics Inc Stock (GANX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Islam Khalid
Executive Chairman
Aug 09 '24
Buy
1.00
50,000
49,940
50,000
RICHMAN ERIC I
Director
Jul 01 '24
Buy
1.22
17,000
20,670
289,629
$20.73
price up icon 1.02%
$35.27
price down icon 1.78%
$21.32
price up icon 0.24%
$101.74
price down icon 2.97%
$106.14
price up icon 1.28%
biotechnology ONC
$254.49
price down icon 4.73%
Cap:     |  Volume (24h):